Supernus Pharmaceuticals, Inc. (SUPN) Financials

SUPN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.5 billion 423.9 million
Dec. 31, 2025 1.5 billion 390.9 million
Sept. 30, 2025 1.4 billion 370.1 million
June 30, 2025 1.4 billion 318.5 million

SUPN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 66.5 million 8.5 million
Dec. 31, 2025 19.4 million 33.1 million
Sept. 30, 2025 -61.8 million 7.8 million
June 30, 2025 58.1 million 7.5 million

SUPN Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 -2.3 million
Dec. 31, 2025 -38.6 million
Sept. 30, 2025 -45.1 million
June 30, 2025 22.5 million

SUPN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 384.2 million - 30.3 million
Dec. 31, 2025 308.7 million - 41.0 million
Sept. 30, 2025 281.2 million - 31.4 million
June 30, 2025 522.6 million - 31.8 million

SUPN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 57.6 million
Dec. 31, 2025 57.3 million
Sept. 30, 2025 56.6 million
June 30, 2025 56.6 million

SUPN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 39.4 million 125.2 million -
Dec. 31, 2025 427000 27.8 million 122.4 million 83.2 million
Sept. 30, 2025 129000 29.4 million 179.7 million 77.1 million
June 30, 2025 455000 22.1 million 93.6 million 65.1 million

SUPN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 207.7 million 23.4 million
Dec. 31, 2025 211.6 million 23.0 million
Sept. 30, 2025 192.1 million 19.0 million
June 30, 2025 165.5 million 16.8 million

SUPN Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SUPN

Price: $44.94

52 week price:
30.83
59.68

Earnings Per Share: -0.51 USD

Exchange: NGM

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 524852

Ebitda: 27.4 million

Market Capitalization: 2.6 billion

Links: